Tango Therapeutics, Inc.
TNGX
$6.61
$0.111.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -42.84% | 10.10% | 15.18% | 15.67% | 26.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.84% | 10.10% | 15.18% | 15.67% | 26.16% |
| Cost of Revenue | 0.92% | 13.63% | 24.93% | 25.12% | 18.04% |
| Gross Profit | -20.99% | -15.13% | -29.46% | -29.82% | -14.65% |
| SG&A Expenses | 13.55% | 16.82% | 23.22% | 21.81% | 19.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.79% | 14.38% | 24.53% | 24.35% | 18.44% |
| Operating Income | -18.75% | -15.64% | -27.52% | -27.32% | -16.16% |
| Income Before Tax | -25.00% | -18.47% | -28.03% | -23.31% | -9.00% |
| Income Tax Expenses | -1.71% | 16.09% | 55.22% | 49.28% | 52.17% |
| Earnings from Continuing Operations | -24.96% | -18.46% | -28.07% | -23.34% | -9.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.96% | -18.46% | -28.07% | -23.34% | -9.05% |
| EBIT | -18.75% | -15.64% | -27.52% | -27.32% | -16.16% |
| EBITDA | -19.11% | -15.92% | -28.04% | -27.80% | -16.19% |
| EPS Basic | -17.33% | -7.26% | -9.47% | -5.39% | 6.65% |
| Normalized Basic EPS | -14.61% | -4.54% | -8.52% | -5.81% | 6.31% |
| EPS Diluted | -17.33% | -7.26% | -9.47% | -5.39% | 6.65% |
| Normalized Diluted EPS | -14.61% | -4.54% | -8.52% | -5.81% | 6.31% |
| Average Basic Shares Outstanding | 6.64% | 11.52% | 16.96% | 16.78% | 16.55% |
| Average Diluted Shares Outstanding | 6.64% | 11.52% | 16.96% | 16.78% | 16.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |